References
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6 :1–158. doi: 10.1111/hae.14046.
- Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol 2018; 11(11): 835–846. doi: 10.1080/17474086.2018.1531701.
- Kenet G, Fujii T. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real-world evidence. Haemophilia 2024; 30(2): 267–275. doi: 10.1111/hae.14933.
- US Food & Drug Administration. FDA approves emicizumabkxwh for hemophilia A with or without factor VIII inhibitors [Internet]. FDA; 2019. Available from:
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumab-kxwh-hemophilia-or-without-factor-viii-inhibitors (accessed November 2022). - Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377(9): 809–818. doi: 10.1056/NEJMoa1703068.
- Young G, Liesner R, Chang T, S et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134(24): 2127–2138. doi: 10.1182/blood.2019001869.
- Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without Inhibitors. N Engl J Med 2018; 379(9): 811–822. doi: 10.1056/NEJMoa1803550.
- Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019; 6(6): e295–305. doi: 10.1016/S2352-3026(19)30054-7.
- Mancuso ME, Mahlangu J, Sidonio R, et al. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors – Results from the HAVEN 2 study. Haemophilia 2020; 26(6): 1009–1018. doi: 10.1111/hae.14183.
- Recht M, Neufeld EJ, Sharma VR, , et al. Impact of acute bleeding on daily activities of patients with congenital hemophilia with inhibitors and their caregivers and families: observations from the Dosing Observational Study in Hemophilia (DOSE). Value Health 2014;17(6): 744–7448. doi: 10.1016/j.jval.2014.07.003.
- Pollak E, Mühlan H, VON Mackensen S, Bullinger M, Haemo-QoL Group. The Haemo-QoL Index: developing a short measure for health-related quality of life assessment in children and adolescents with haemophilia. Haemophilia 2006; 12(4): 384–392. doi: 10.1111/j.1365-2516.2006.01292.x.
- Von Mackensen S. Quality of life and sports activities in patients with haemophilia. Haemophilia 2007; 13 Suppl 2 :38–43. doi: 10.1111/j.1365-2516.2007.01505.x.
- Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf 2016; 25(1): 2–10. doi: 10.1002/pds.3891.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human USE (ICH). Integrated Addendum to ICH E6 (R1): Guideline for good clinical practice E6 (R2). Current Step 4 version. Dated 9 November 2016. Available from
https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf . - Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood 2021; 137(16): 2231–2242. doi: 10.1182/blood.2020009217.
- McCary I, Guelcher C, Kuhn J, et al. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures. Haemophilia 2020; 26(4): 631–636. doi: 10.1111/hae.14005.
- Liu G, Huang K, Li G, et al. Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China. Front Pediatr 2022; 10: 992267. doi: 10.3389/fped.2022.992267.
- Arcudi S, Gualtierotti R, Marino S, et al. Real-world data on emicizumab prophylaxis in the Milan cohort. Haemophilia 2022; 28(5): e141–144. doi: 10.1111/hae.14630.
- Hahn SM, Han JW, Kim JS, et al. Real-world data for the use of emicizumab in haemophilia A patients with inhibitors – First nationwide report from Korea. Haemophilia 2023; 29(4): 1163–1166. doi: 10.1111/hae.14819.
- Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PloS One 2013; 8(2): e57479. doi: 10.1371/journal.pone.0057479.
- Aviña-Zubieta JA, Galindo-Rodriguez G, Lavalle C. Rheumatic manifestations of hematologic disorders. Curr Opin Rheumatol 1998; 10(1): 86–90. doi: 10.1097/00002281-199801000-00013.
- Chu WM, Ho HE, Wang JD, et al. Risk of major comorbidities among workers with hemophilia: A 14-year population-based study. Medicine (Baltimore) 2018; 97(6): e9803. doi: 10.1097/MD.0000000000009803.
- Borhany M, Arshad A, Qureshi H, Nadeem R, Jamal A, Ahmed Khan R. Emicizumab prophylaxis in patients with severe hemophilia A: insights from a resource limited country. Clin Appl Thromb Hemost 2024; 30: 10760296231224357. doi: 10.1177/10760296231224357.
- Oladapo AO, Lu M, Walsh S, O’Hara J, Kauf TL. Inhibitor clinical burden of disease: a comparative analysis of the CHESS data. Orphanet J Rare Dis 2018; 13(1): 198. doi: 10.1186/s13023-018-0929-9.
- Mahlangu J, Oldenburg J, Callaghan MU, et al. Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia 2019; 25(3): 382–391. doi: 10.1111/hae.13731.
- Wiley RE, Khoury CP, Snihur AWK, et al. From the voices of people with haemophilia A and their caregivers: Challenges with current treatment, their impact on quality of life and desired improvements in future therapies. Haemophilia 2019; 25(3): 433–440. doi: 10.1111/hae.13754.
- Jiménez-Yuste V, Peyvandi F, Klamroth R, et al. Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY). Res Pract Thromb Haemost 2022; 6(8): e12837. doi: 10.1002/rth2.12837.
- Oka G, Roussel-Robert V, Levivien C, Lopez I, Pieragostini R. Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy. Haemophilia 2023; 29(3): 709–715. doi: 10.1111/hae.14755.
- Skinner MW, Négrier C, Paz-Priel I, et al. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia 2021; 27(5): 854–865. doi: 10.1111/hae.14363.